SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NSIX -- Neuromedical Systems, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard James who wrote (78)3/25/1998 11:19:00 AM
From: TLWatson59   of 137
 
The JAMA article reported on an Air Force study which used a narrow sample group of women as the focal point of a conclusion that "Automated or computerized screens" failed to significantly deliver results that were different than double manual screening. The group used for the model consisted of Air Force female personnel who were subject to annual physical exams as well as 100% PAP smear testing.

Any normal evaluation of such a study would have to recognize that any conclusions drawn from such a study group could not possibly be representative. The responses from all of the companies offering automated and computerized evaluations were quick to point out these short comings. Those companies such as NSI offered the rebuttal that in order to receive FDA approval for their processes test data involving hundreds of thousands of women from every economic and social strata had to be submitted and the results documented. It was noted that even in the population used by the Air Force PAPNET found at least one or two false negatives in the study

The fact of the matter is that there are distinct groups with personal practice and profit motives competitive to those of ACYT, CYTC, DIGE, NPTH and NSIX and they have strong allies in certain segments of Professional Media and public forums through which they attack the validity and economic value of these new technologies. I firmly believe it is just a matter of time before the true value both diagnostic and economic prove themselves in this segment of the medical testing industry and take their rightful place as leaders.

Individual investors however must make their own decision as to how they want to participate in this new wave technology. At this still early stage of development and competition strong partisan support of one company and its technology over the other is not the wisest course IMO. The stock price ranges of the companies cited above are not that far different from one another to preclude establishing a group fund in which the investor could then weight the dollar participation in a manner that gives them the most comfort. Then hold on for the next year or two for what could be a very profitable ride.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News